Cue Biopharma
CUE
49 hedge funds and large institutions have $51.8M invested in Cue Biopharma in 2026 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 21 closing their positions.
947% more capital invested
Capital invested by funds: $4.95M → $51.8M (+$46.9M)
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
38.35% more ownership
Funds ownership: 0.73% → 39.08% (+38%)
11% less funds holding
Funds holding: 55 → 49 (-6)
29% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 21
64% less call options, than puts
Call options by funds: $114K | Put options by funds: $316K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$6.61M |
| 2 |
BL
Bleichroeder LP
New York
|
+$3.24M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.36M |
| 4 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$2.12M |
| 5 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$1.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GWMR
GC Wealth Management RIA
Cambridge,
Massachusetts
|
-$1.06M |
| 2 |
LPC
Lion Point Capital
New York
|
-$463K |
| 3 |
RSWM
Robertson Stephens Wealth Management
San Francisco,
California
|
-$109K |
| 4 |
AWM
Angeles Wealth Management
Santa Monica,
California
|
-$75.4K |
| 5 |
CPIG
Chicago Partners Investment Group
Chicago,
Illinois
|
-$49.9K |
CUE Hedge Fund Activity: Q2 2026 in Review
49 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q2 2026, worth a combined $51.8M — up 947% from $4.95M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of CUE and 15 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 20 added.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $6.61M. The largest seller was GC Wealth Management RIA, exiting entirely with an estimated $1.06M sold.
- 49 institutional investors held Cue Biopharma (CUE) as of Q2 2026, down from 55 in Q1 2026.
- Funds reported $51.8M of Cue Biopharma stock for Q2 2026, up 947% quarter-over-quarter.
- 15 funds opened new Cue Biopharma positions in Q2 2026 and 21 closed out, a net change of -6 holders.
- The largest Cue Biopharma buyer in Q2 2026 was Driehaus Capital Management, an estimated $6.61M added.
- The largest Cue Biopharma seller in Q2 2026 was GC Wealth Management RIA, an estimated $1.06M sold.
Based on aggregated 13F filings for Q2 2026.